Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 89, Issue 7, 2013, Pages 321-339

  Saido, Takaomi C ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Alzheimer's disease (AD); Amyloid peptide (A ); Metabolism; Mild cognitive impairment (MCI); Neprilysin; Preclinical AD; Secretase

Indexed keywords

EID: 84880945264     PISSN: 03862208     EISSN: 13492896     Source Type: Journal    
DOI: 10.2183/pjab.89.321     Document Type: Review

References (139)

1. Flicker, C., Ferris, S.H. and Reisberg, B. (1991) Mild cognitive impairment in the elderly: predictors of dementia. Neurology 41, 1006-1009.
2. Golomb, J., Kluger, A. and Ferris, S.H. (2000) Mild cognitive impairment: identifying and treating the earliest stages of Alzheimer's disease. Neurosci. News 3, 46-53.
3. Asada, T. (2003) Study on the risk factors and preventive interventions of dementing disorders. Kokateki Iryogijutsuno Kakuritsu Suishin Rinshoukenkyuujigyoou, Ministry of Health, Labor and Welfare of Japan. 1-5.
4. Braak, H. and Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
5. Funato, H., Enya, M., Yoshimura, M., Morishima- Kawashima, M. and Ihara, Y. (1999) Presence of sodium dodecyl sulfate-stable amyloid O-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am. J. Pathol. 155, 23-28.
6. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., Holtzman, D.M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P.S., Ghetti, B., Klunk, W.E., McDade, E., Martins, R.N., Masters, C.L., Mayeux, R., Ringman, J.M., Rossor, M.N., Schofield, P.R., Sperling, R.A., Salloway, S. and Morris J.C.; Dominantly Inherited Alzheimer Network (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804.
7. Chong, M.S. and Sahadevan, S. (2005) Preclinical Alzheimer's disease: diagnosis and prediction of progression. Lancet Neurol. 4, 576-579.
8. Masters, C.L. and Selkoe, D.J. (2012) Biochemistry of amyloid O-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect Med. doi:10.1101/cshperspect.a006262.
9. Kwon, J. (2002) http://www.alzforum.org/res/com/mut/tau/default.asp.
10. Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
11. Higuchi, M., Lee, V.M. and Trojanowski, J.Q. (2002) Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med. 2, 131-150.
12. Forman, M.S., Trojanowski, J.Q. and Lee, V.M. (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10, 1055-1063.
13. Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., Raux, G., Camuzat, A., Penet, C., Mesnage, V., Martinez, M., Clerget-Darpoux, F., Brice, A. and Frebourg, T. (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664-670.
14. Hardy, J. (2012) http://www.alzforum.org/res/com/mut/pre/default.asp.
15. Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M.N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J. and Younkin, S. (1996) Increased amyloid-O42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713.
16. Nakano, Y., Kondoh, G., Kudo, T., Imaizumi, K., Kato, M., Miyazaki, J., Tohyama, M., Takeda, J. and Takeda, M. (1999) Accumulation of murine amyloidO42 in a gene-dosage-dependent manner in PS1 'knock-in' mice. Eur. J. Neurosci. 11, 2577-2581.
17. Demeester, N., Mertens, C., Caster, H., Goethals, M., Vandekerckhove, J., Rosseneu, M. and Labeur, C. (2001) Comparison of the aggregation properties, secondary structure and apoptotic effects of wild-type, Flemish and Dutch Nterminally truncated amyloid β peptides. Eur. J. Neurosci. 13, 2015-2024.
18. Nilsberth, C., Westlind-Danielsson, A., Eckman, C.B., Condron, M.M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D.B., Younkin, S.G., Naslund, J. and Lannfelt, L. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced AO protofibril formation. Nat. Neurosci. 4, 887-893.
19. Murakami, K., Irie, K., Morimoto, A., Ohigashi, H., Shindo, M., Nagao, M., Shimizu, T. and Shirasawa, T. (2002) Synthesis, aggregation, neurotoxicity, and secondary structure of various AO1-42 mutants of familial Alzheimer's disease at positions 21-23. Biochem. Biophys. Res. Commun. 294, 5-10.
20. Yamamoto, N., Matsuzaki, K. and Yanagisawa, K. (2005) Cross-seeding of wild-type and hereditary variant-type amyloid beta-proteins in the presence of gangliosides. J. Neurochem. 95, 1167- 1176.
21. Tsubuki, S., Takaki, Y. and Saido, T.C. (2003) Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of AO to physiologically relevant proteolytic degradation. Lancet 361, 1957-1958.
22. Wakutani, Y., Watanabe, K., Adachi, Y., Wada-Isoe, K., Urakami, K., Ninomiya, H., Saido, T.C., Hashimoto, T., Iwatsubo, T. and Nakashima, K. (2004) Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1039-1042.
23. Funato, H., Yoshimura, M., Kusui, K., Tamaoka, A., Ishikawa, K., Ohkoshi, N., Namekata, K., Okeda, R. and Ihara, Y. (1998) Quantitation of amyloid O-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am. J. Pathol. 152, 1633-1640.
24. Wang, J., Dickson, D.W., Trojanowski, J.Q. and Lee, V.M. (1999) The levels of soluble versus insoluble brain AO distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158, 328-337.
25. Morishima-Kawashima, M., Oshima, N., Ogata, H., Yamaguchi, H., Yoshimura, M., Sugihara, S. and Ihara, Y. (2000) Effect of apolipoprotein E allele e4 on the initial phase of amyloid O-protein accumulation in the human brain. Am. J. Pathol. 157, 2093-2099.
26. Saunders, A.M., Trowers, M.K., Shimkets, R.A., Blakemore, S., Crowther, D.J., Mansfield, T.A., Wallace, D.M., Strittmatter, W.J. and Roses, A.D. (2000) The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochim. Biophys. Acta 1502, 85-94.
27. Shoji, M., Golde, T.E., Ghiso, J., Cheung, T.T., Estus, S., Shaffer, L.M., Cai, X.D., McKay, D.M., Tintner, R., Frangione, B. and Younkin, S.G. (1992) Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258, 126-129.
28. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I. and Schenk, D. (1992) Isolation and quantification of soluble Alzheimer's O-peptide from biological fluids. Nature 359, 325-327.
29. van Gool, W.A., Schenk, D.B. and Bolhuis, P.A. (1994) Concentrations of amyloid-O protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease. Neurosci. Lett. 172, 122-124.
30. Mattson M.P. (1997) Cellular actions of O-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77, 1081-1132.
31. Oltersdorf, T., Fritz, L.C., Schenk, D.B., Lieberburg, I., Johnson-Wood, K.L., Beattie, E.C., Ward, P.J., Blacher, R.W., Dovey, H.F. and Sinha, S. (1989) The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature 341, 144-147.
32. Miyazaki, K., Hasegawa, M., Funahashi, K. and Umeda, M. (1993) A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature 362, 839-841.
33. Koo, E.H. and Kopan, R. (2004) Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat. Med. 10 (Suppl.), S26-S33.
34. Kim, H.S., Kim, E.M., Lee, J.P., Park, C.H., Kim, S., Seo, J.H., Chang, K.A., Yu, E., Jeong, S.J., Chong, Y.H. and Suh, Y.H. (2003) C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3O expression. FASEB J. 17, 1951-1953.
35. Kitazume, S., Tachida, Y., Oka, R., Shirotani, K., Saido, T.C. and Hashimoto, Y. (2001) Alzheimer's O-secretase, O-site amyloid precursor proteincleaving enzyme, is responsible for cleavage secretion of a golgi-resident sialyltransferease. Proc. Natl. Acad. Sci. U.S.A. 98, 13554-13559.
36. Hartmann, D. (2003) Functional roles of APP secretases. In AO Metabolism and Alzheimer's Disease (ed. Saido, T.C.). Landes Bioscience, Georgetown, pp. 49-60.
37. Lichtenthaler, S.F., Dominguez, D., Westmeyer, G.G., Reiss, K., Haass, C., Saftig, P., De Strooper, B. and Seed, B. (2003) The cell adhesion protein p-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278, 48713-48719.
38. Li, Q. and Südhof, T.C. (2004) Cleavage of amyloid-β precursor protein and amyloid-O precursor-like protein by BACE1. J. Biol. Chem. 279, 10542- 10550.
39. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L. and Wong, P.C. (2001) BACE1 is the major O-secretase for generation of AO peptides by neurons. Nat. Neurosci. 4, 233-234.
40. Dominguez, D., Tournoy, J., Hartmann, D., Huth, T., Cryns, K., Deforce, S., Serneels, L., Camacho, I.E., Marjaux, E., Craessaerts, K., Roebroek, A.J., Schwake, M., D'Hooge, R., Bach, P., Kalinke, U., Moechars, D., Alzheimer, C., Reiss, K., Saftig, P. and De Strooper, B. (2005) Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J. Biol. Chem. 280, 30797-30806.
41. Saido, T.C. (1998) Alzheimer's disease as proteolytic disorders: anabolism and catabolism of Oamyloid. Neurobiol. Aging 19, S69-S75.
42. Saido, T.C. (2003) Overview-AO metabolism: from Alzheimer research to brain aging control. In AO Metabolism and Alzheimer's Disease (ed. Saido, T.C.). Landes Bioscience, Georgetown, pp. 1-16.
43. Ishiura, S., Asai, M., Hattori, C., Hotoda, N., Szabo, B., Sasagawa, N. and Tanuma, S. (2003) APP ,-secretase, a novel target for Alzheimer drug therapy. In AO Metabolism and Alzheimer's Disease (ed. Saido, T.C.). Landes Bioscience, Georgetown, pp. 27-32.
44. Zlokovic, B.V., Yamada, S., Holtzman, D., Ghiso, J. and Frangione, B. (2000) Clearance of amyloid O-peptide from brain: transport or metabolism?. Nat. Med. 6, 718.
45. Iwata, N., Tsubuki, S., Hama, E., Takaki, Y., Shirotani, K. and Saido, T.C. (2000) Reply to: 'Clearance of amyloid O-peptide from brain: transport or metabolism?'. Nat. Med. 6, 718-719.
46. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T.D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D. and Younkin, S. (1996) Secreted amyloid O-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870.
47. Vanderstichele, H., Van Kerschaver, E., Hesse, C., Davidsson, P., Buyse, M.A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K. and Vanmechelen, E. (2000) Standardization of measurement of O-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
48. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D. and Seubert, P. (1999) Immunization with amyloid-O attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400, 173-177.
49. Zlokovic, B.V. and Frangione, B. (2003) Transportclearance hypothesis for Alzheimer's disease and potential therapeutic implications. In AO Metabolism and Alzheimer's Disease (ed. Saido, T.C.). Landes Bioscience, Georgetown, pp. 117-125.
50. DeMattos, R.B., Bales, K.R., Cummins, D.J., Paul, S.M. and Holtzman, D.M. (2002) Brain to plasma amyloid-O efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267.
51. Lemere, C.A., Beierschmitt, A., Iglesias, M., Spooner, E.T., Bloom, J.K., Leverone, J.F., Zheng, J.B., Seabrook, T.J., Louard, D., Li, D., Selkoe, D.J., Palmour, R.M. and Ervin, F.R. (2004) Alzheimer's disease AO vaccine reduces central nervous system AO levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 165, 283-297.
52. Schenk, D. (2003) Amyloid-O immunotherapy for Alzheimer's disease. The end of the beginning. Nat. Rev. Neurosci. 3, 824-828.
53. Saido, T.C., Iwatsubo, T., Mann, D.M., Shimada, H., Ihara, Y. and Kawashima, S. (1995) Dominant and differential deposition of distinct O-amyloid peptide species, AON3(pE), in senile plaques. Neuron 14, 457-466.
54. Kawarabayashi, T., Younkin, L.H., Saido, T.C., Shoji, M., Ashe, K.H. and Younkin, S.G. (2001) Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381.
55. Saido, T.C., Yamao-Harigaya, W., Iwatsubo, T. and Kawashima, S. (1996) Amino- and carboxylterminal heterogeneity of O-amyloid peptides deposited in human brain. Neurosci. Lett. 215, 173-176.
56. Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.J., Hama, E., Sekine-Aizawa, Y. and Saido, T.C. (2000) Identification of the major AO1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143- 150.
57. Lemere, C.A., Lopera, F., Kosik, K.S., Lendon, C.L., Ossa, J., Saido, T.C., Yamaguchi, H., Ruiz, A., Martinez, A., Madrigal, L., Hincapie, L., Arango L., J.C., Anthony, D.C., Koo, E.H., Goate, A.M., Selkoe, D.J. and Arango, J.C. (1996) The E280A Presenilin 1 mutation leads to a distinct Alzheimer's disease phenotype: Increased AO42 deposition and severe cerebellar pathology. Nat. Med. 2, 1146-1150.
58. Citron, M. (2003) O-Secretase: Progress and open questions. In AO Metabolism and Alzheimer's Disease (ed. Saido, T.C.). Landes Bioscience, Georgetown, pp. 17-25.
59. Wolfe, M. (2003) .-Secretase and presenilin. In AO Metabolism and Alzheimer's Disease (ed. Saido, T.C.). Landes Bioscience, Georgetown, pp. 33-47.
60. Turner, A.J. (2004) Neprilysin. In Handbook of Proteolytic Enzymes (eds. Barrett, A.J., Rawlings, N.D., Woessner, J.F.). Academic Press, London, pp. 419-426.
61. Dolev, I. and Michaelson, D.M. (2004) A nontransgenic mouse model shows inducible amyloid-β (Aβ) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc. Natl. Acad. Sci. U.S.A. 101, 13909-13914.
62. Takaki, Y., Iwata, N., Tsubuki, S., Taniguchi, S., Toyoshima, S., Lu, B., Gerard, N.P., Gerard, C., Lee, H.J., Shirotani, K. and Saido, T.C. (2000) Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid β peptide in the brain. J. Biochem. 128, 897-902.
63. Shirotani, K., Tsubuki, S., Iwata, N., Takaki, Y., Harigaya, W., Maruyama, K., Kiryu-Seo, S., Kiyama, H., Iwata, H., Tomita, T., Iwatsubo, T. and Saido, T.C. (2001) Neprilysin degrades both amyloid β peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J. Biol. Chem. 276, 21895-21901.
64. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P., Gerard, C., Hama, E., Lee, H.J. and Saido, T.C. (2001) Metabolic regulation of brain AO by neprilysin. Science 292, 1550- 1552.
65. Roques, B.P., Noble, F., Dauge, V., Fournie-Zaluski, M.C. and Beaumont, A. (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 45, 87-146.
66. Turner, A.J., Isaac, R.E. and Coates, D. (2001) The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23, 261-269.
67. Fukami, S., Watanabe, K., Iwata, N., Haraoka, J., Lu, B., Gerard, N.P., Gerard, C., Fraser, P., Westaway, D., St. George-Hyslop, P. and Saido, T.C. (2002) AO-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with AO pathology. Neurosci. Res. 43, 39-56.
68. Iwata, N., Higuchi, M. and Saido, T.C. (2005) Metabolism of amyloid-O peptide and Alzheimer's disease. Pharmacol. Ther. 108, 129-148.
69. Kiryu-Seo, S., Sasaki, M., Yokohama, H., Nakagomi, S., Hirayama, T., Aoki, S., Wada, K. and Kiyama, H. (2000) Damage-induced neuronal endopeptidase (DINE) is a unique metallopeptidase expressed in response to neuronal damage and activates superoxide scavengers. Proc. Natl. Acad. Sci. U.S.A. 97, 4345-4350.
70. Lu, B., Gerard, N.P., Kolakowski, L.F. Jr., Bozza, M., Zurakowski, D., Finco, O., Carroll, M.C. and Gerard, C. (1995) Neutral endopeptidase modulation of septic shock. J. Exp. Med. 181, 2271- 2275.
71. Saido, T.C. and Nakahara, H. (2003) Proteolytic degradation of AO by neprilysin and other peptidases. In AO Metabolism and Alzheimer's Disease (ed. Saido, T.C.). Landes Bioscience, Georgetown, pp. 61-80.
72. Eckman, E.A. and Eckman, C.B. (2003) AO degradation by endothelin-converting enzymes. In AO Metabolism and Alzheimer's Disease (ed. Saido, T.C.). Landes Bioscience, Georgetown, pp. 81-94.
73. Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Volitakis, I., Fraser, F.W., Kim, Y., Huang, X., Goldstein, L.E., Moir, R.D., Lim, J.T., Beyreuther, K., Zheng, H., Tanzi, R.E., Masters, C.L. and Bush, A.I. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits O-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676.
74. Yasojima, K., Akiyama, H., McGeer, E.G. and McGeer, P.L. (2001a) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of O-amyloid peptide. Neurosci. Lett. 297, 97-100.
75. Yasojima, K., McGeer, E.G. and McGeer, P.L. (2001b) Relationship between β amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 919, 115- 121.
76. Iwata, N., Takaki, Y., Fukami, S., Tsubuki, S. and Saido, T.C. (2002) Region-specific reduction of AO-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70, 493-500.
77. Wang, D.S., Iwata, N., Hama, E., Saido, T.C. and Dickson, D.W. (2003) Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 310, 236-241.
78. Wang, D.S., Lipton, R.B., Katz, M.J., Davies, P., Buschke, H., Kuslansky, G., Verghese, J., Younkin, S.G., Eckman, C. and Dickson, D.W. (2005) Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J. Neuropathol. Exp. Neurol. 64, 378-385.
79. Russo, R., Borghi, R., Markesbery, W., Tabaton, M. and Piccini, A. (2005) Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett. 579, 6027-6030.
80. Miners, J.S., van Helmond, Z., Kehoe, P.G. and Love, S. (2010) Changes with age in the activities of O-secretase and the AO-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol. 20, 794- 802, doi:10.1111/j.1750-3639.2010.00375.x.
81. Hellström-Lindahl, E., Ravid, R. and Nordberg, A. (2008) Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with AO levels. Neurobiol. Aging 29, 210-221.
82. Wang, S., Wang, R., Chen, L., Bennett, D.A., Dickson, D.W. and Wang, D.S. (2010) Expression and functional profiling of neprilysin, insulindegrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J. Neurochem. 115, 47-57.
83. Gómez-Isla, T., Price, J.L., McKeel, D.W. Jr., Morris, J.C., Growdon, J.H. and Hyman, B.T. (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491-4500.
84. Mèlanie, C., Robitalle, Y., DesGroseillers, L., Boileau, G. and Marcinkiewicz, M. (2002) Declining expression of neprilysin in Alzheimer disease vasculature: possible involvment in cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 61, 849-856.
85. Akiyama, H., Kondo, H., Ikeda, K., Kato, M. and McGeer, P.L. (2001) Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid O-protein (Aβ) deposition. Brain Res. 902, 277- 281.
86. Marr, R.A., Rockenstein, E., Mukherjee, A., Kindy, M.S., Hersh, L.B., Gage, F.H., Verma, I.M. and Masliah, E. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23, 1992-1996.
87. Leissring, M.A., Farris, W., Chang, A.Y., Walsh, D.M., Wu, X., Sun, X., Frosch, M.P. and Selkoe, D.J. (2003) Enhanced proteolysis of O-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093.
88. Iwata, N., Mizukami, H., Shirotani, K., Takaki, Y., Muramatsu, S., Lu, B., Gerard, N.P., Gerard, C., Ozawa, K. and Saido, T.C. (2004) Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-O peptide in mouse brain. J. Neurosci. 24, 991-998.
89. Caccamo, A., Oddo, S., Sugarman, M.C., Akbari, Y. and LaFerla, F. (2005) Age- and region-dependent alterations in AO-degrading enzymes: implications for AO-induced disorders. Neurobiol. Aging 26, 645-654.
90. Saido, T.C. (2000) Degradation of amyloid-O peptide: a key to Alzheimer pathogeneis, prevention, and therapy. NeuroSci. News 5, 52-62.
91. Hama, E., Shirotani, K., Masumoto, H., Sekine-Aizawa, Y., Aizawa, H. and Saido, T.C. (2001) Clearance of extracellular and cell-associated amyloid β peptide through viral expression of neprilysin in primary neurons. J. Biochem. 130, 721-726.
92. Marr, R.A., Rockenstein, E., Mukherjee, A., Kindy, M.S., Hersh, L.B., Gage, F.H., Verma, I.M. and Masliah, E. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23, 1992-1996.
93. Spencer, B., Marr, R.A., Rockenstein, E., Crews, L., Adame, A., Potkar, R., Patrick, C., Gage, F.H., Verma, I.M. and Masliah, E. (2008) Long-term neprilysin gene transfer is associated with reduced levels of intracellular AO and behavioral improvement in APP transgenic mice. BMC Neurosci. 9, 109, doi:10.1186/1471-2202-9-109.
94. Iwata, N., Sekiguchi, M., Hattori, Y., Takahashi, A., Asai, M., Ji, B., Higuchi, M., Staufenbiel, M., Muramatsu, S. and Saido, T.C. (2013) Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci. Rep. 3, 1472, doi:10.1038/srep01472.
95. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., Frosch, M.P., Eckman, C.B., Tanzi, R.E., Selkoe, D.J. and Guenette, S. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid O-protein, and the Oamyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 4162- 4167.
96. Gasparini, L., Gouras, G.K., Wang, R., Gross, R.S., Beal, M.F., Greengard, P. and Xu, H. (2001) Stimulation of O-amyloid precursor protein trafficking by insulin reduces intraneuronal O-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21, 2561-2570.
97. Solano, D.C., Sironi, M., Bonfini, C., Solerte, S.B., Govoni, S. and Racchi, M. (2000) Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J. 14, 1015-1022.
98. Finelli, A., Kelkar, A., Song, H.-J., Yang, H. and Konsolaki, M. (2004) A model for studying Alzheimer's AO42-induced toxicity in Drosophila melanogaster. Mol. Cell. Neurosci. 26, 365-375.
99. Hama, E., Shirotani, K., Iwata, N. and Saido, T.C. (2004) Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid β peptide clearance in primary neurons. J. Biol. Chem. 279, 30259-30264.
100. Saito, T., Iwata, N., Tsubuki, S., Takaki, Y., Takano, J., Huang, S.M., Suemoto, T., Higuchi, M. and Saido, T.C. (2005) Somatostatin regulates brain amyloid β peptide, AO42, via modulation of proteolytic degradation. Nat. Med. 11, 434-439.
101. Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J. and Ashe, K.H. (2004) Natural oligomers of the amyloid-O protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84.
102. Kanemitsu, H., Tomiyama, T. and Mori, H. (2003) Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett. 350, 113-116.
103. Huang, S.M., Mouri, A., Kokubo, H., Nakajima, R., Suemoto, T., Higuchi, M., Staufenbiel, M., Noda, Y., Yamaguchi, H., Nabeshima, T., Saido, T.C. and Iwata, N. (2006) Neprilysin-sensitive synapseassociated amyloid-O peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281, 17941-17951.
104. Morelli, L., Llovera, R., Gonzalez, S.A., Affranchino, J.L., Prelli, F., Frangione, B., Ghiso, J. and Castano, E.M. (2003) Differential degradation of amyloid β genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J. Biol. Chem. 278, 23221-23226.
105. Saito, T., Takaki, Y., Iwata, N., Trojanowski, J. and Saido, T.C. (2003) Perspectives: Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-O peptide metabolism. SAGE-KE, doi:10.1126/sageke.2003.3.pe1.
106. Wang, T.-L., Chang, H., Hung, C.-R. and Tseng, Y.-Z. (1998) Morphine preconditioning attenuates neutrophil activation in rat models of myocardial infarction. Cardiovasc. Res. 40, 557-563.
107. Joshi, D.D., Dang, A., Yadav, P., Qian, J., Bandari, P.S., Chen, K., Donnelly, R., Castro, T., Gascon, P., Haider, A. and Rameshwar, P. (2001) Negative feedback on the effect of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: a combined functional and proteomic study. Blood 98, 2697-2706.
108. Moller, L.N., Stidsen, C.E., Hartmann, B. and Holst, J.J. (2003) Somatostatin receptors. Biochim. Biophys. Acta 1616, 1-84.
109. Bruno, J.F., Xu, Y., Song, J. and Berelowitz, M. (1992) Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc. Natl. Acad. Sci. U.S.A. 89, 11151-11155.
110. Doggrell, S.A. (2004) The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease. Expert Opin. Investig. Drugs 13, 69-72.
111. Hayashi, M., Yamashita, A. and Shimizu, K. (1997) Somatostatin and brain-derived neurotrophic factor mRNA expression in the primate brain: decreased levels of mRNA during aging. Brain Res. 749, 283-289.
112. Lu, T., Pan, Y., Kao, S.Y., Li, C., Kohane, I., Chan, J. and Yankner, B.A. (2004) Gene regulation and DNA damage in the ageing human brain. Nature 429, 883-891.
113. Davies, P., Katzman, R. and Terry, R.D. (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia. Nature 288, 279- 280.
114. Hama, E. and Saido, T.C. (2005) Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid β peptide. Med. Hypotheses 65, 498-500.
115. Storey, E. and Capprai, R. (1999) The amyloid precursor protein of Alzheimer's disease and the AO peptide. Neuropathol. Appl. Neurobiol. 25, 81-97.
116. Li, R., Lindholm, K., Yang, L.B., Yue, X., Citron, M., Yan, R., Beach, T., Sue, L., Sabbagh, M., Cai, H., Wong, P., Price, D. and Shen, Y. (2004) Amyloid β peptide load is correlated with increased O-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. U.S.A. 101, 3632-3637.
117. Lemere, C.A., Spooner, E.T., Leverone, J.F., Mori, C., Iglesias, M., Bloom, J.K. and Seabrook, T.J. (2003) Amyloid-O immunization in Alzheimer's disease transgenic mouse models and wildtype mice. Neurochem. Res. 28, 1017-1027.
118. Asai, M., Iwata, N., Tomita, T., Iwatsubo, T., Ishiura, S., Saido, T.C. and Maruyama, K. (2010) Efficient four-drug cocktail therapy targeting amyloid-O peptide for Alzheimer's disease. J. Neurosci. Res. 88, 3588-3597.
119. Flexner, C. (2000) Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu. Rev. Pharmacol. Toxicol. 40, 649-674.
120. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, W.S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I.R., McGeer, P.L., O'Banion, M.K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F.L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G. and Wyss-Coray, T. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
121. Cairns, N.J., Lee, V.M. and Trojanowski, J.Q. (2004) The cytoskeleton in neurodegenerative diseases. J. Pathol. 204, 438-449.
122. Saito, K., Elce, J.S., Hamos, J.E. and Nixon, R.A. (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 90, 2628-2632.
123. Higuchi, M., Tomioka, M., Takano, J., Shirotani, K., Iwata, N., Masumoto, H., Maki, M., Itohara, S. and Saido, T.C. (2005) Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice over-expressing their specific inhibitors. J. Biol. Chem. 280, 15229-15237.
124. Takano, J., Tomioka, M., Tsubuki, T., Higuchi, M., Iwata, N., Itohara, S., Maki, M. and Saido, T.C. (2005) Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways: evidence from calpastatin-mutant mice. J. Biol. Chem. 280, 16175-16184.
125. Higuchi, M., Iwata, N., Matsuba, Y., Takano, J., Suemoto, T., Maeda, J., Ji, B., Ono, M., Staufenbiel, M., Suhara, T. and Saido, T.C. (2012) Mechanistic involvement of the calpaincalpastatin system in Alzheimer neuropathology. FASEB J. 26, 1204-1217.
126. Lewis, J., Dickson, D.W., Lin, W.L., Chisholm, L., Corral, A., Jones, G., Yen, S.H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, M. and McGowan, E. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
127. Götz, J., Chen, F., van Dorpe, J. and Nitsch, R.M. (2001) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by AO 42 fibrils. Science 293, 1491-1495.
128. Nixon, R.A. (2003) The calpains in aging and agingrelated diseases. Ageing Res. Rev. 2, 407-418.
129. Cribbs, D.H., Poon, W.W., Rissman, R.A. and Blurton-Jones, M. (2004) Caspase-mediated degeneration in Alzheimer's disease. Am. J. Pathol. 165, 353-355.
130. Roth, K.A. (2001) Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. J. Neuropathol. Exp. Neurol. 60, 829-838.
131. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
132. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K. and Suzuki, T. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302- 305.
133. Goldberg, M.S., Fleming, S.M., Palacino, J.J., Cepeda, C., Lam, H.A., Bhatnagar, A., Meloni, E.G., Wu, N., Ackerson, L.C., Klapstein, G.J., Gajendiran, M., Roth, B.L., Chesselet, M.F., Maidment, N.T., Levine, M.S. and Shen, J. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628-43635.
134. Miller, B.C., Eckman, E.A., Sambamurti, K., Dobbs, N., Chow, K.M., Eckman, C.B., Hersh, L.B. and Thiele, D.L. (2003) Amyloid-O peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 6221-6226.
135. Ertekin-Taner, N., Ronald, J., Feuk, L., Prince, J., Tucker, M., Younkin, L., Hella, M., Jain, S., Hackett, A., Scanlin, L., Kelly, J., Kihiko-Ehman, M., Neltner, M., Hersh, L., Kindy, M., Markesbery, W., Hutton, M., de Andrade, M., Petersen, R.C., Graff-Radford, N., Estus, S., Brookes, A.J. and Younkin, S.G. (2005) Elevated amyloid β protein (AO42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum. Mol. Genet. 14, 447-460.
136. Tucker, H.M., Simpson, J., Kihiko-Ehmann, M., Younkin, L.H., McGillis, J.P., Younkin, S.G., Degen, J.L. and Estus, S. (2004) Plasmin deficiency does not alter endogenous murine amyloid β levels in mice. Neurosci. Lett. 368, 285-289.
137. Suzuki, N., Cheung, T.T., Cai, X.D., Odaka, A., Otvos, L. Jr., Eckman, C., Golde, T.E. and Younkin, S.G. (1994) An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (OAPP717) mutants. Science 264, 1336-1340.
138. Lafrance, M.H., Vezina, C., Wang, Q., Boileau, G., Crine, P. and Lemay, G. (1994) Role of glycosylation in transport and enzymic activity of neutral endopeptidase-24.11. Biochem. J. 302, 451-454.
139. Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E. and Bateman, R.J. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.